Press releases
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
- Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
- Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
- Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
More ▼
Key statistics
On Friday, Lineage Cell Therapeutics Inc (BT3:BER) closed at 1.01, 29.49% above the 52 week low of 0.78 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.01 |
Low | 1.01 |
Bid | 1.04 |
Offer | 1.08 |
Previous close | 0.995 |
Average volume | 169.00 |
---|---|
Shares outstanding | 188.53m |
Free float | 180.75m |
P/E (TTM) | -- |
Market cap | 214.93m USD |
EPS (TTM) | -0.1243 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:08 BST.
More ▼